AREA OF EXPERTISE
Finance, Therapeutic Area Strategies, Corporate Strategy
US Commercial News, Scrip and Pink Sheet
YEARS OF INDUSTRY EXPERIENCE
Mandy Jackson is Managing Editor for US Commercial News, counting finance, therapeutic area strategies and corporate strategy among her areas of expertise. With 20-plus years as a journalist and more than a decade covering biopharma, Mandy leads Scrip’s financial coverage, writing the weekly Finance Watch column and quarterly IPO updates as well as annual financial reviews and forecasts.
The biopharmaceutical industry in 2021 has already broken records set only last year in terms of venture capital fundraising and initial public offerings. New company formation and accumulation of growth capital are fueling biopharma innovation at unprecedented levels, generating new therapeutic candidates for patients – and assets for big pharma portfolios – at a rapid pace. Rising valuations for start-ups and growth-stage firms makes for a challenging environment for companies looking to acquire external innovation, but the market for licensing deals and collaborations is robust.
Scrip's team of trusted industry experts bring you the most critical news and analysis on key commercial topics, from licensing to clinical trials, and competitor activity, around the clock..
Our global team of journalists and editors use their extensive experience and relationships with regulators, associations, and industry leaders to bring you in-depth insights so you can stay current on the latest market developments.
Register for your free trial today to find out what our editors and journalists are reporting on now.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: